DNLI
DNLI clinical trials: Denali Therapeutics Inc.
Every trial on ClinicalTrials.gov where Denali Therapeutics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 26
- Trials linked
- 19
- As lead sponsor
- 7
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
DNLI on the catalyst calendar · DNLI registry changes
- Primary completion Aug 2028Sponsor estimatePhase 1/Phase 2NCT07354724A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe DiseaseDenali Therapeutics Inc. · Late-onset Pompe DiseaseRecruitingDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2/Phase 3NCT06075537An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With...Denali Therapeutics Inc. · Mucopolysaccharidosis IIEnrolling by invitationDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2032Sponsor estimatePhase 1/Phase 2NCT06181136Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)Denali Therapeutics Inc. · Mucopolysaccharidosis Type IIIARecruitingDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2/Phase 3NCT05371613A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With...Denali Therapeutics Inc. · Mucopolysaccharidosis IIActive, not recruitingDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2030Sponsor estimatePhase 1NCT07758595A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With...Denali Therapeutics Inc. · Alzheimer's DiseaseRecruitingDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 1NCT07328451A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's...Denali Therapeutics Inc. · Alzheimer Disease, Early OnsetRecruitingDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 2NCT06602193Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)Denali Therapeutics Inc. · Parkinson DiseaseActive, not recruitingDNLILeadBIIBCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05262023A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants...Denali Therapeutics Inc. · Frontotemporal DementiaActive, not recruitingDNLILeadTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2031Sponsor estimatePhase 1/Phase 2NCT04251026A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter SyndromeDenali Therapeutics Inc. · Mucopolysaccharidosis IIActive, not recruitingDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2022ActualPhase 1NCT05006352A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral SclerosisDenali Therapeutics Inc. · Amyotrophic Lateral SclerosisCompletedDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2024ActualPhase 1NCT06281158A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male...Denali Therapeutics Inc. · Healthy VolunteersCompletedDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2024ActualNo phase registeredNCT04007536A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter SyndromeDenali Therapeutics Inc. · Mucopolysaccharidosis IICompletedDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 8, 2023ActualPhase 1NCT05450549A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy ParticipantsDenali Therapeutics Inc. · Healthy ParticipantCompletedDNLILeadTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 19, 2021ActualPhase 1NCT04557800A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy VolunteersDenali Therapeutics Inc. · Healthy VolunteersCompletedDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2021ActualPhase 1NCT04268784A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy VolunteersDenali Therapeutics Inc. · Healthy VolunteersCompletedDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 4, 2021ActualPhase 1NCT04581772A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy VolunteersDenali Therapeutics Inc. · Healthy VolunteersCompletedDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 8, 2018ActualPhase 1NCT04551534A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy VolunteersDenali Therapeutics Inc. · Healthy VolunteersCompletedDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 5, 2019ActualPhase 1NCT03757325Study to Evaluate DNL747 in Subjects With Alzheimer's DiseaseDenali Therapeutics Inc. · Alzheimer DiseaseCompletedDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 6, 2019ActualPhase 1NCT03710707Study to Evaluate DNL201 in Subjects With Parkinson's DiseaseDenali Therapeutics Inc. · Parkinson DiseaseCompletedDNLILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2024ActualPhase 2/Phase 3NCT05842941HEALEY ALS Platform Trial - Regimen G DNL343Merit E. Cudkowicz, MD · Amyotrophic Lateral SclerosisCompletedDNLICollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 9, 2026ActualPhase 2NCT05348785A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in...Biogen · Parkinson DiseaseCompletedBIIBLeadDNLICollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 18, 2020ActualPhase 1NCT03757351Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral SclerosisSanofi · Amyotrophic Lateral SclerosisTerminatedSNYLeadDNLICollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2024ActualNo phase registeredNCT05523206A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)Sanguine Biosciences · Mucopolysaccharidosis III-ACompletedDNLICollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 27, 2023ActualPhase 3NCT05418673A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific...Biogen · Parkinson DiseaseTerminatedBIIBLeadDNLICollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 5, 2021ActualPhase 1NCT05119790A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male SubjectsBiogen · Healthy VolunteersCompletedBIIBLeadDNLICollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 1 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner